

EVRY, February 23, 2016 PRESS RELEASE

Myology 2016

5th edition of the International Myology Congress of the AFM-Telethon from 14 to 18 March at the Palais des congrès of Lyon

30 years after the discovery of the Duchenne muscular dystrophy gene, myology started leading in the field of innovative therapies

The 5th International Myology Congress organized by the AFM-Telethon, will bring together more than 800 world experts (doctors, researchers, clinicians) from 14 to 18 March at the Palais des congrès of Lyon. This event will be the highlight of the international myology in 2016, 30 years right after the discovery of the gene responsible of Duchenne muscular dystrophy, announced in 1986 Tours Congress also organized by the AFM-Telethon association.

In 30 years, research has grown from a beginner science to the emergence of the first treatments against neuromuscular diseases. **Over 70 myology** experts representing five continents will present their latest work at Myology 2016. Nearly **450 posters** will also be proposed to members of congress. **10 plenary sessions and 14 symposia** will discuss current issues of myology such as stem cells in muscle development, neuromuscular interactions, therapeutic approaches, particularly the most innovative (gene therapy, exon skipping, pharmacogenomics...), the latest advances in treatment for heart, a vital muscle...

The Highlights of Myology 2016

Monday, March 14 at 6pm: Inaugural conference of 30th anniversary of the discovery of Duchenne muscular dystrophy gene by Kenneth Fischbeck (one of the author of the publication) Tuesday, March 15: fundamental muscle biology and neuromuscular junction Wednesday, March 16 and Thursday, March 17: focus on therapeutic trials or in development for neuromuscular diseases Friday, March 18: Zoom on the heart and advanced therapies currently under development (cell therapy, gene therapy); Closing conference on innovative technology Crispr9 and its application to Duchenne

muscular dystrophy.

Therefore, Myology 2016 will be marked by therapeutic progress, the increasing number of clinical trials and the first drugs embarked on the path of Marketing Authorisation Application. A turning point which is reflected in particular by the increased presence of industry at this congress.

The complexity of neuromuscular diseases is a real challenge for all stakeholders in international research. Neuromuscular diseases result in movement disorders due to damage of muscle itself or of neuromuscular junction. They have origins, developments and degrees of severity different. Neuromuscular diseases can touch not only the traction members but also multiple functions depending on the muscle skills such as eye movement, deglutition, digestion, breathing or heart function. Numbering about 200, they are mostly genetic.

Myology 2016

For more information: http://www.myology2016.org/fr/

Presidents:

H. Lee Sweeney (University of Florida, USA) Laurent Schaeffer (ENS, Lyon, France)

Scientific Committee:

Jon Andoni-Urtizberea (Hendaye, France) Jean-Marie Gillis (Brussels, Belgium) Serge Braun (Evry, France) Shahragim Tajbashsh (Paris, France) Enrico Bertini (Rome, Italy) Nathalie Goemans (Leuven, Belgium) Years T.Van der Ploeg (Rotterdam, Netherlands) Carole Vuillerot (Lyon, France) Lucie Carrier (Hamburg, Germany)

For further information and to organize your stay:

Karima Jaoudi – Phone : 01.69.47.11.71/ 06.11.63.85.17 presse@afm-telethon.fr